Cancer screening unlikely to benefit patients with a short life expectancy

January 8, 2013

Breast and colorectal cancer screening should be targeted towards patients with a life expectancy greater than 10 years: for any shorter life expectancy the harms are likely to outweigh the benefits, concludes a study published in BMJ today.

The authors that their results "should not be used to deny screening for with limited life expectancy" but "should inform which aims to account for patient preferences and values while maximising benefits and minimising risks."

Guidelines recommend screening healthy older patients because complications from screening can harm patients immediately while the benefits of screening are not seen for many years.

What still remains unclear, however, is how long a patient needs to live to benefit from . Previous trials have focused on the size of benefit rather than when those benefits occur.

Researchers from the University of California in San Francisco therefore analysed the results of five breast and four colorectal cancer screening trials focusing on patients aged over 50.

Their goal was to estimate the time-lag to benefit (the time between screening and when the benefits of screening are seen) to determine whether an individual patient is likely to benefit from screening.

The trials were published between 1986 and 2008 and ranged in size from just under 40,000 people to just over 150,000 people. Follow-up ranged from 8-20 years.

Results showed that at five years, an average 2.8 colorectal cancer deaths were prevented for every 10,000 people screened. This benefit steadily increased with longer follow-up, reaching 23 colorectal cancer deaths prevented for every 10,000 people screened at 15 years.

In absolute terms, it took an average of 4.8 years to prevent one colorectal cancer death for 5,000 people screened and 10.3 years to prevent one death for 1,000 people screened.

For breast cancer, at five years an average of 5.1 deaths were prevented for every 10,000 women screened. By 15 years, this mortality benefit had increased to 19 breast cancer deaths prevented for every 10,000 women screened.

In absolute terms, it took an average of three years to prevent one breast for 5.000 women screened and 10.7 years to prevent one death for 1,000 women screened.

However, the researchers say that in both colorectal and breast cancer, approximately one in ten people screened will have a false positive result and many more will be subject to possibly unnecessary treatment.

Based on these results, they suggest that patients with a life expectancy greater than ten years "should be encouraged to undergo colorectal and screening" but patients whose is 3-5 years "probably should be discouraged from screening since the potential risks likely outweigh the very small probability of benefit."

They conclude that incorporating time lag estimates into screening guidelines "would encourage a more explicit consideration of the risks and benefits of breast and screening, likely resulting in a more individualised decision making process for the heterogeneous population of older adults."

Explore further: Study finds mammography screening reduces breast cancer mortality

More information: Time-lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom and Denmark, BMJ, 2013.

Related Stories

Study finds mammography screening reduces breast cancer mortality

June 28, 2011
Breast cancer screening with mammography results in a significant reduction in breast cancer mortality, according to long-term follow-up results of a large-scale Swedish trial. The results are published online in the journal ...

ACP releases new colorectal cancer screening guidance statement

March 5, 2012
The American College of Physicians (ACP) today issued a new guidance statement for colorectal cancer screening. Colorectal cancer is the second leading cause of cancer-related deaths for men and women in the United States. ...

Depression affected preventive health screening among Latina breast cancer survivors

September 19, 2011
Depression, in addition to other barriers, may prevent Latina breast cancer survivors from undergoing preventive health screening for colorectal and ovarian cancer, according to data presented at the Fourth AACR Conference ...

New study supports claim that breast screening may be causing more harm than good

December 9, 2011
A new study published on bmj.com today supports the claim that the introduction of breast cancer screening in the UK may have caused more harm than good.

Too many americans skipping colon cancer screening

March 2, 2012
(HealthDay) -- Approximately one in three U.S. adults between the ages of 50 and 75 who should be screened for colorectal cancer have not been, according to the American Society for Gastrointestinal Endoscopy.

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.